Replimune (REPL) Depreciation & Amortization (CF) (2017 - 2026)
Replimune (REPL) reported Depreciation & Amortization (CF) of $700000.0 for Q1 2026, down 17.26% on a YoY basis from $846000.0 in Q1 2025, and down 12.5% sequentially from $800000.0 in Q4 2025.
Replimune (REPL) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Replimune (REPL) has 10 years of Depreciation & Amortization (CF) data on file, last reported at $700000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 17.26% year-over-year to $700000.0; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (down 8.1% YoY), and the FY2026 full-year result was $3.3 million, down 5.71% from the prior year.
- Depreciation & Amortization (CF) retreated to $700000.0 in Q1 2026, from $800000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.0 million in Q4 2024 to a low of $481000.0 in Q1 2023.
- A 5-year average of $724117.6 and a median of $700000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) jumped 46.57% in 2024 and decreased 20.0% in 2025, its largest moves.
- Tracing REPL's Depreciation & Amortization (CF) over 5 years: stood at $682000.0 in 2022, then rose by 2.64% to $700000.0 in 2023, then jumped by 42.86% to $1.0 million in 2024, then fell by 20.0% to $800000.0 in 2025, then dropped by 12.5% to $700000.0 in 2026.
- Business Quant data shows REPL's Depreciation & Amortization (CF) at $700000.0 in Q1 2026, $800000.0 in Q4 2025, and $800000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - | 700,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 700,000.00 |
| Mar 31, 2026 | 700,000.00 |
| Dec 31, 2025 | 800,000.00 |
| Dec 31, 2025 | 800,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 900,000.00 |
| Mar 31, 2025 | 846,000.00 |
| Mar 31, 2025 | 846,000.00 |
| Dec 31, 2024 | 1.00 Mn |
| Dec 31, 2024 | 1.00 Mn |
| Sep 30, 2024 | 900,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 736,000.00 |
| Jun 30, 2024 | 736,000.00 |
| Mar 31, 2024 | 705,000.00 |
| Mar 31, 2024 | 705,000.00 |
| Dec 31, 2023 | 700,000.00 |
| Dec 31, 2023 | 700,000.00 |